{"id":"rhinocort","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Epistaxis","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Pharyngitis","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Bronchospasm","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Coughing","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Nasal Irritation","drugRate":"2%","severity":"common","organSystem":""}],"contraindications":["Acute tuberculosis","Adrenal cortical hypofunction","Bacterial infectious disease","Bilateral cataracts","Disease caused by parasite","Disease of liver","Epistaxis","Exposure to varicella","Glaucoma","Inactive tuberculosis","Measles","Mycobacteriosis","Mycosis","Nasal Candidiasis","Nasal Septal Ulcers","Nasal Trauma","Ocular hypertension","Operation on nose","Ophthalmic herpes simplex","Perforation of nasal septum","Uncontrolled Bacterial Infections","Untreated Fungal Infection","Varicella-zoster virus infection"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Anaphylaxis","drugRate":"","severity":"serious"},{"effect":"Nasal Septum Perforation","drugRate":"","severity":"serious"},{"effect":"Candida albicans Infection","drugRate":"","severity":"serious"},{"effect":"Immunosuppression","drugRate":"","severity":"serious"},{"effect":"Adrenal Suppression","drugRate":"","severity":"serious"},{"effect":"Hypercorticism/Cushing's Syndrome","drugRate":"","severity":"serious"},{"effect":"Growth Suppression","drugRate":"","severity":"serious"},{"effect":"Glaucoma","drugRate":"","severity":"serious"},{"effect":"Cataracts","drugRate":"","severity":"serious"},{"effect":"Angioedema","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":["Budesonide"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Rhinocort","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:24:53.697763+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Rhinocort","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T01:25:00.316883+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:24:58.583656+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rhinocort","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:24:59.095614+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Glucocorticoid receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:25:00.316804+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1370/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:24:59.914974+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"ffca32a2-fbef-40bb-b0f0-73f63e18e747","title":"RHINOCORT AQUA (BUDESONIDE) SPRAY, METERED [PHYSICIANS TOTAL CARE, INC.]"},"ecosystem":[],"mechanism":{"target":"Matrix metalloproteinase-9, Probable G-protein coupled receptor 97, Glucocorticoid receptor"},"_scrapedAt":"2026-03-27T23:31:56.652Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Budesonide","title":"Budesonide","extract":"Budesonide, sold under the brand name Pulmicort, among others, is a steroid medication. It is available as an inhaler, nebulization solution, pill, nasal spray, and rectal foam. The inhaled form is used in the long-term management of asthma and chronic obstructive pulmonary disease (COPD). The nasal spray is used for allergic rhinitis and nasal polyps. Modified-release pills or capsules and rectal forms may be used for inflammatory bowel disease including Crohn's disease, ulcerative colitis, and microscopic colitis."},"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:25:01.638419+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Allergic rhinitis","diseaseId":"allergic-rhinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Asthma","diseaseId":"asthma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Asthma management","diseaseId":"asthma-management","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Nasal polyp","diseaseId":"nasal-polyp","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Rhinitis","diseaseId":"rhinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Vasomotor rhinitis","diseaseId":"vasomotor-rhinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07491991","phase":"PHASE4","title":"Effects of Different Drugs for Glottic Atomization on Postoperative Sore Throat After Thyroid Surgery","status":"COMPLETED","sponsor":"Qianfoshan Hospital","startDate":"2025-03-02","conditions":"Postoperative Pain, NEBULIZATION, Thyroid Surgery","enrollment":96},{"nctId":"NCT06676319","phase":"PHASE2","title":"Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-11-07","conditions":"Asthma","enrollment":1147},{"nctId":"NCT06712563","phase":"","title":"Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-04-17","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2000},{"nctId":"NCT06860542","phase":"PHASE2","title":"Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2026-02-10","conditions":"Pneumonitis, Immune-related Adverse Event","enrollment":94},{"nctId":"NCT05405387","phase":"PHASE2","title":"Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Utah","startDate":"2023-05-03","conditions":"Multiple Myeloma, Plasma Cell Leukemia","enrollment":120},{"nctId":"NCT07073950","phase":"PHASE4","title":"A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-24","conditions":"Chronic Obstructive Pulmonary Disease, Hyperinflation","enrollment":56},{"nctId":"NCT06531798","phase":"PHASE4","title":"Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-19","conditions":"Moderate to Severe COPD","enrollment":150},{"nctId":"NCT05862545","phase":"","title":"Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-06-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":250},{"nctId":"NCT07069829","phase":"","title":"Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-15","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1400},{"nctId":"NCT05309590","phase":"","title":"Efficacy of Low-Dose Topical Steroids in Maintaining Remission of Eosinophilic Esophagitis in Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2014-05","conditions":"Eosinophilic Esophagitis","enrollment":50},{"nctId":"NCT06471257","phase":"PHASE3","title":"A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-06-17","conditions":"Asthma","enrollment":790},{"nctId":"NCT07426458","phase":"PHASE4","title":"Ventilation and Perfusion in Asthmatics","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-04","conditions":"Asthma","enrollment":40},{"nctId":"NCT07433569","phase":"PHASE1","title":"A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-05","conditions":"Asthma","enrollment":12},{"nctId":"NCT06473779","phase":"PHASE3","title":"Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-30","conditions":"Severe Asthma","enrollment":326},{"nctId":"NCT06596252","phase":"PHASE3","title":"Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE","status":"RECRUITING","sponsor":"Dr. Falk Pharma GmbH","startDate":"2021-05-21","conditions":"Eosinophilic Esophagitis","enrollment":308},{"nctId":"NCT07267130","phase":"PHASE1","title":"A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.","startDate":"2025-11-25","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":57},{"nctId":"NCT06307665","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-05-20","conditions":"Asthma","enrollment":440},{"nctId":"NCT06334575","phase":"PHASE4","title":"Molecular Signatures Associated With Response to ICS Treatment in Patients With COPD Stratified by Eosinophil Levels","status":"RECRUITING","sponsor":"Maria Joyera Rodríguez","startDate":"2025-02-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":135},{"nctId":"NCT06067828","phase":"PHASE3","title":"A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-10-24","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":171},{"nctId":"NCT06283966","phase":"PHASE3","title":"A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-02-21","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":5000},{"nctId":"NCT06076304","phase":"PHASE4","title":"Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis","status":"RECRUITING","sponsor":"Daniel Merenstein","startDate":"2023-11-21","conditions":"Sinus Infection, Acute Sinusitis","enrollment":3720},{"nctId":"NCT06563102","phase":"PHASE4","title":"Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-09-11","conditions":"Mild Asthma","enrollment":101},{"nctId":"NCT07156175","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-10-14","conditions":"Microscopic Colitis","enrollment":54},{"nctId":"NCT05562466","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-05-11","conditions":"Asthma","enrollment":200},{"nctId":"NCT05839756","phase":"NA","title":"Predicting Post Extubation Stridor After Maxillomandibular Fixation","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2023-05-03","conditions":"Stridor, Larynx Edema","enrollment":62},{"nctId":"NCT07414134","phase":"","title":"Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe Exacerbation","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-10-31","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":3598},{"nctId":"NCT06502366","phase":"PHASE3","title":"A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-07-22","conditions":"Asthma","enrollment":422},{"nctId":"NCT06712407","phase":"PHASE4","title":"Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy","status":"RECRUITING","sponsor":"Calliditas Therapeutics AB","startDate":"2024-12-17","conditions":"IgA Nephropathy","enrollment":60},{"nctId":"NCT07386873","phase":"NA","title":"The Efficacy of Olfactory Cleft Steroid Drops in Patients With CRS With Olfactory Cleft Obstruction","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2026-03-01","conditions":"Chronic Rhinosinusitis (CRS), Smell Dysfunction","enrollment":54},{"nctId":"NCT07386860","phase":"NA","title":"The Effectiveness of Steroid Nasal Drops in the Olfactory Cleft Combined With Olfactory Training for Patients With PIOD","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2026-03-01","conditions":"Smell Dysfunction","enrollment":100},{"nctId":"NCT07383402","phase":"PHASE3","title":"Intra-Sinus Povidone-Iodine and Budesonide After Endoscopic Sinus Surgery for Chronic Rhinosinusitis","status":"NOT_YET_RECRUITING","sponsor":"Amin Javer","startDate":"2026-03-30","conditions":"Chronic Rhinosinusitis (CRS)","enrollment":180},{"nctId":"NCT06905483","phase":"PHASE4","title":"Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study","status":"COMPLETED","sponsor":"Thammasat University","startDate":"2025-04-01","conditions":"COPD, Chronic Obstructive Pulmonary Disease (COPD), Small Airway Disease","enrollment":22},{"nctId":"NCT05202262","phase":"PHASE3","title":"A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-01-12","conditions":"Asthma","enrollment":645},{"nctId":"NCT07372573","phase":"NA","title":"Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler","status":"NOT_YET_RECRUITING","sponsor":"University of Health Sciences Lahore","startDate":"2026-02-01","conditions":"Asthma (Diagnosis)","enrollment":210},{"nctId":"NCT05755906","phase":"PHASE3","title":"A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-02-27","conditions":"Asthma","enrollment":374},{"nctId":"NCT05555290","phase":"PHASE3","title":"PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-09-28","conditions":"Asthma","enrollment":190},{"nctId":"NCT06855043","phase":"PHASE1, PHASE2","title":"Little Lungs Study","status":"NOT_YET_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-09","conditions":"Invasive Mechanical Ventilation, Severe Respiratory Distress Syndrome","enrollment":24},{"nctId":"NCT04545866","phase":"PHASE3","title":"The Budesonide in Babies (BiB) Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"NICHD Neonatal Research Network","startDate":"2021-04-01","conditions":"Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome, Prematurity; Extreme","enrollment":642},{"nctId":"NCT00584636","phase":"PHASE4","title":"Pulmicort Respules on Relapse Rates After Treatment in the ED","status":"WITHDRAWN","sponsor":"Phoenix Children's Hospital","startDate":"2007-10","conditions":"Asthma","enrollment":""},{"nctId":"NCT04294641","phase":"PHASE2","title":"Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-10","conditions":"Chronic GVHD","enrollment":10},{"nctId":"NCT07358234","phase":"EARLY_PHASE1","title":"Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-02","conditions":"Eosinophilic Esophagitis (EoE)","enrollment":60},{"nctId":"NCT07352488","phase":"NA","title":"Modified Shenling Baizhu Powder for Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Henan University of Traditional Chinese Medicine","startDate":"2026-01-15","conditions":"Allergic Asthma","enrollment":400},{"nctId":"NCT06429475","phase":"PHASE3","title":"Anti-Inflammatory Reliever South Africa","status":"RECRUITING","sponsor":"University of KwaZulu","startDate":"2024-06-06","conditions":"Asthma","enrollment":1038},{"nctId":"NCT06676007","phase":"","title":"A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy","status":"RECRUITING","sponsor":"Sichuan Provincial People's Hospital","startDate":"2024-10-30","conditions":"IgA Nephropathy (IgAN), Early Initial Therapy","enrollment":200},{"nctId":"NCT07329946","phase":"NA","title":"Immuno-inflammatory Response of Erdosteine in COPD","status":"NOT_YET_RECRUITING","sponsor":"Pierachille Santus, MD, PhD","startDate":"2026-02-28","conditions":"COPD","enrollment":30},{"nctId":"NCT07318350","phase":"PHASE3","title":"Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA)","status":"NOT_YET_RECRUITING","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-10","conditions":"Moderate Asthma","enrollment":174},{"nctId":"NCT04361474","phase":"PHASE3","title":"Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity","status":"COMPLETED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2020-05-18","conditions":"Budesonide, Olfaction Disorders, SARS-CoV-2","enrollment":120},{"nctId":"NCT06422689","phase":"PHASE4","title":"Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-05-10","conditions":"Asthma","enrollment":1507},{"nctId":"NCT06368427","phase":"","title":"Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-04-30","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":10},{"nctId":"NCT05735431","phase":"PHASE3","title":"Non-Inferiority,Combination Formoterol/FluticasonexAlenia®Formoterol/Budesonide for Asthma in Brazil","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-06","conditions":"Moderate Asthma","enrollment":""},{"nctId":"NCT06110403","phase":"PHASE1, PHASE2","title":"Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2023-09-29","conditions":"Copd","enrollment":35},{"nctId":"NCT07270302","phase":"PHASE1, PHASE2","title":"Nebulized Nasal Steroids","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-12","conditions":"Chronic Rhinosinusitis","enrollment":50},{"nctId":"NCT06321731","phase":"","title":"Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-07-02","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":718},{"nctId":"NCT03952286","phase":"PHASE4","title":"ED-Initiated School-based Asthma Medication Supervision","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2019-08-01","conditions":"Asthma, Asthma in Children","enrollment":13},{"nctId":"NCT06027606","phase":"PHASE1","title":"Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2023-09-01","conditions":"Healthy","enrollment":81},{"nctId":"NCT03250975","phase":"PHASE1, PHASE2","title":"Incidence of Acute Laryngeal Injury Following Endotracheal Intubation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2017-08-19","conditions":"Intubation Complication","enrollment":64},{"nctId":"NCT07052942","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care (Full Study)","status":"RECRUITING","sponsor":"DARTNet Institute","startDate":"2025-08-01","conditions":"Asthma, Asthma Attack, Asthma Exacerbations","enrollment":3200},{"nctId":"NCT06422676","phase":"","title":"MultIceNtre Non-intERVentional Study for Efficacy,Safety Evaluation of BREZTRI in Pts With COPD in RussiA","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-12-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":4},{"nctId":"NCT07193485","phase":"NA","title":"Efficacy of Buteyko Breathing in Seniors With Chronic Eustachian Tube Dysfunction","status":"RECRUITING","sponsor":"Cairo University","startDate":"2025-05-12","conditions":"Eustachian Tube Dysfunction","enrollment":40},{"nctId":"NCT05878093","phase":"PHASE3","title":"Dupilumab in Chinese Adult Participants With CRSwNP","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-05-16","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":63},{"nctId":"NCT03992469","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-02-15","conditions":"Crohn's Disease","enrollment":7},{"nctId":"NCT05573464","phase":"PHASE3","title":"A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-09-27","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":559},{"nctId":"NCT06590740","phase":"PHASE4","title":"Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-10-18","conditions":"Cough-Variant Asthma","enrollment":1000},{"nctId":"NCT05976802","phase":"PHASE4","title":"Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis","status":"NOT_YET_RECRUITING","sponsor":"Bausch Health Americas, Inc.","startDate":"2027-06","conditions":"Ulcerative Colitis","enrollment":100},{"nctId":"NCT05689983","phase":"PHASE1, PHASE2","title":"Symptom-driven ICS/LABA Therapy for Adolescent Patients With Asthma Non-adherent to Daily Maintenance Inhalers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-04-01","conditions":"Asthma in Children, Nonadherence, Medication","enrollment":40},{"nctId":"NCT05111262","phase":"PHASE1, PHASE2","title":"Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2021-12-16","conditions":"Asthma, Nonadherence, Medication","enrollment":60},{"nctId":"NCT04314375","phase":"PHASE4","title":"Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis","status":"RECRUITING","sponsor":"Bausch Health Americas, Inc.","startDate":"2023-09-29","conditions":"Ulcerative Colitis","enrollment":70},{"nctId":"NCT07030894","phase":"PHASE4","title":"Nefecon and Ambrisentan in IgA Nephropathy","status":"RECRUITING","sponsor":"The First Hospital of Jilin University","startDate":"2025-09-01","conditions":"IgA Nephropathy, Chronic Kidney Disease, Proteinuria","enrollment":129},{"nctId":"NCT06830109","phase":"PHASE2","title":"Nasal Obstruction With Oxymetazoline and Corticosteroids","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-10-15","conditions":"Nasal Obstruction","enrollment":80},{"nctId":"NCT05477108","phase":"PHASE1","title":"Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":108},{"nctId":"NCT06075095","phase":"PHASE3","title":"A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-01-11","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":297},{"nctId":"NCT06744374","phase":"","title":"A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-02-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22369},{"nctId":"NCT06245551","phase":"PHASE3","title":"A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-12-22","conditions":"Asthma, Exercise-Induced","enrollment":64},{"nctId":"NCT06514157","phase":"PHASE1","title":"Phase I PK Study of Budesonide/Albuterol Delivered From PT027 in Healthy Chinese Participants.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-08-19","conditions":"Healthy Volunteer","enrollment":14},{"nctId":"NCT05569421","phase":"PHASE1","title":"A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-10-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":108},{"nctId":"NCT04193878","phase":"PHASE3","title":"ARrest RESpiraTory Failure From PNEUMONIA","status":"TERMINATED","sponsor":"Stanford University","startDate":"2020-06-01","conditions":"Pneumonia, Hypoxemia, Acute Respiratory Failure","enrollment":465},{"nctId":"NCT06340581","phase":"PHASE1","title":"A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2024-10-17","conditions":"Healthy","enrollment":""},{"nctId":"NCT07103642","phase":"","title":"EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-08-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3402},{"nctId":"NCT06297668","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-04-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":42},{"nctId":"NCT07114107","phase":"NA","title":"Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-08","conditions":"Atopic Rhinitis, Atopic Asthma","enrollment":200},{"nctId":"NCT06742736","phase":"","title":"EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-05-31","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":13000},{"nctId":"NCT05505734","phase":"PHASE3","title":"A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma","status":"COMPLETED","sponsor":"Bond Avillion 2 Development LP","startDate":"2022-09-02","conditions":"Asthma","enrollment":2516},{"nctId":"NCT04374474","phase":"PHASE4","title":"Anosmia Rehabilitation in Patients Post Coronavirus Disease (COVID 19)","status":"WITHDRAWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2021-01-10","conditions":"Olfactory Disorder","enrollment":""},{"nctId":"NCT04480242","phase":"","title":"Asthma Research in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2017-07-26","conditions":"Persistent Asthma, Asthma in Children, Asthma Exacerbation","enrollment":525},{"nctId":"NCT07081399","phase":"EARLY_PHASE1","title":"the Effect of Adult Intubated Patient Clinical Pathway on Post-extubation Complications Prevention","status":"RECRUITING","sponsor":"Damanhour University","startDate":"2024-08-08","conditions":"Dysphagia, Dysphagia Rehabilitation","enrollment":80},{"nctId":"NCT06209047","phase":"PHASE4","title":"Bronchoscopic Levofloxacin, Gentamicin, or Sham for Acute Exacerbation of Bronchiectasis","status":"RECRUITING","sponsor":"Assiut University","startDate":"2023-10-15","conditions":"Bronchiectasis With Acute Exacerbation","enrollment":315},{"nctId":"NCT06676384","phase":"PHASE4","title":"Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?","status":"RECRUITING","sponsor":"Christian Medical College, Vellore, India","startDate":"2025-02-15","conditions":"IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis","enrollment":585},{"nctId":"NCT05213611","phase":"","title":"REported Outcomes in COPD With Trixeo in Real worlD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-08-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":150},{"nctId":"NCT07058259","phase":"NA","title":"Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul Medeniyet University","startDate":"2024-11-15","conditions":"COPD (Chronic Obstructive Pulmonary Disease), Acupuncture","enrollment":60},{"nctId":"NCT05311306","phase":"","title":"REported Outcomes in COPD With Trixeo in Real worlD in Germany","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-03-15","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":475},{"nctId":"NCT03705793","phase":"PHASE4","title":"Effectiveness of Mometasone Nasal Irrigation for Chronic Rhinosinusitis","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-01-01","conditions":"Chronic Rhinosinusitis (Diagnosis), Allergic Rhinosinusitis, Chronic Eosinophilic Rhinosinusitis","enrollment":53},{"nctId":"NCT06895460","phase":"PHASE3","title":"A Trial on the Treatment of Bronchial Asthma With Budesonide Formoterol Combined With Immune Modulators (Staphylococcus and Neisseria Tablets)","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-06-20","conditions":"Bronchial Asthma","enrollment":198},{"nctId":"NCT06723756","phase":"PHASE1","title":"A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-01-23","conditions":"Healthy Participants","enrollment":105},{"nctId":"NCT01167010","phase":"PHASE3","title":"A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2011-04","conditions":"Asthma","enrollment":552},{"nctId":"NCT03803787","phase":"PHASE2","title":"Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients","status":"RECRUITING","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2018-09-01","conditions":"Radiation Pneumonitis","enrollment":72},{"nctId":"NCT05509933","phase":"PHASE3","title":"Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation","status":"RECRUITING","sponsor":"Henry Ford Health System","startDate":"2022-11-09","conditions":"Engraftment Syndrome","enrollment":110},{"nctId":"NCT06940700","phase":"PHASE2","title":"Clinical Study on the Efficacy and Safety of SHR-4597 Inhalant in Adult Patients With Asthma","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","startDate":"2025-04","conditions":"Asthma","enrollment":60},{"nctId":"NCT06922305","phase":"PHASE1","title":"Relative Bioavailability Study of HR19042 in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-12-27","conditions":"Primary IgA Nephropathy; Autoimmune Hepatitis","enrollment":18},{"nctId":"NCT04609878","phase":"PHASE3","title":"Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-12-15","conditions":"Asthma","enrollment":2274},{"nctId":"NCT06272370","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care","status":"COMPLETED","sponsor":"DARTNet Institute","startDate":"2024-02-01","conditions":"Asthma, Bronchial Diseases, Respiratory Tract Infections","enrollment":103}],"_emaApprovals":[],"_faersSignals":[{"count":432,"reaction":"DYSPNOEA"},{"count":327,"reaction":"DRUG INEFFECTIVE"},{"count":326,"reaction":"ASTHMA"},{"count":308,"reaction":"HEADACHE"},{"count":249,"reaction":"NAUSEA"},{"count":245,"reaction":"PAIN"},{"count":236,"reaction":"COUGH"},{"count":233,"reaction":"DIZZINESS"},{"count":226,"reaction":"MALAISE"},{"count":225,"reaction":"FATIGUE"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL1370"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":53,"therapeuticAreas":["Respiratory"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"approved","brandName":"Rhinocort","genericName":"Rhinocort","companyName":"Marinomed Biotech AG","companyId":"marinomed-biotech-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:25:01.638419+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}